Are You a Carrier? What Your Genes Mean for Your Baby.

BRCA1 is one of your body’s master DNA repair genes. Every time a cell divides, its DNA is vulnerable to breaks and damage. BRCA1 finds these breaks and fixes them before they become mutations that could lead to cancer. Without functional BRCA1, damaged DNA accumulates.

If you carry a pathogenic variant in BRCA1, your cells cannot repair DNA as efficiently as they should. Roughly 1 in 400 people in the general population carry a BRCA1 mutation. Carriers have a 55-72% lifetime risk of breast cancer, meaning more than half of women with BRCA1 mutations will develop breast cancer in their lifetime. The risk begins in the 20s and 30s, not just in older age. Men with BRCA1 mutations also have elevated prostate and other cancer risks.

If your child inherits a BRCA1 mutation from you, they will face early-onset cancer screening requirements from childhood onward. Some families choose preventive surgery. Others choose intensive surveillance. But without knowing in advance, your daughter or son reaches adulthood with a ticking clock they didn’t know was running.

BRCA2 partners with BRCA1 to repair DNA damage. It also controls how cells divide and prevents tumor formation. Together, BRCA1 and BRCA2 act as the cell’s failsafe against runaway growth.

Carrying a pathogenic BRCA2 variant occurs in roughly 1 in 800 people. BRCA2 mutation carriers have a 45-69% lifetime breast cancer risk, plus elevated risk of ovarian cancer, male breast cancer, prostate cancer, and pancreatic cancer. The risk profile overlaps with BRCA1 but extends into more cancer types. Pancreatic cancer is particularly aggressive and often diagnosed late, making BRCA2 carriers vulnerable to one of the deadliest malignancies.

If your child inherits BRCA2, they face the same lifetime cancer surveillance and decision-making as with BRCA1. The cancer types differ slightly, and the risk percentages are somewhat lower, but the lifelong implications are equally profound. Many families discover BRCA2 mutations only after a young relative develops cancer.

MTHFR is the enzyme that converts folate into its active form, methylfolate, which your cells use to build and repair DNA and regulate neurotransmitters. It’s not optional. Every cell division depends on it. It’s also critical to clearing homocysteine, an amino acid that, at elevated levels, damages blood vessel walls and increases clotting risk.

The MTHFR C677T variant, present in roughly 40% of people with European ancestry, reduces this enzyme’s efficiency by 40-70%. Carriers of C677T have impaired homocysteine clearance, meaning elevated homocysteine levels even with adequate folate and B12 intake. Elevated homocysteine is an independent cardiovascular risk factor, linked to heart disease, stroke, and thrombosis, particularly in pregnancy.

If your child inherits the C677T variant (especially if both parents carry it), they may struggle with homocysteine metabolism throughout life. In pregnancy, elevated homocysteine increases miscarriage risk and complications like preeclampsia. This is one of the few carrier conditions where intervention before conception and during pregnancy is proven to reduce risk.

Factor V is a protein that is essential to blood clotting. It works with other factors to activate thrombin, which converts fibrinogen to fibrin, forming stable blood clots. This is critical when you’re bleeding. It’s dangerous when clots form where they shouldn’t.

The Factor V Leiden variant (R506Q), found in roughly 5% of people with European ancestry, makes the clotting factor resistant to being turned off. This increases venous thromboembolism risk by 4-8 fold in carriers; in people taking oral contraceptives, the risk rises 80-fold. Most carriers never have a clot. But pregnancy is itself a hypercoagulable state. Your blood becomes thicker to prevent bleeding during labor. Combined with Factor V Leiden, this can lead to dangerous clotting in the legs (deep vein thrombosis) or lungs (pulmonary embolism).

If your child inherits Factor V Leiden, they need to know it before starting oral contraceptives, before pregnancy, and before surgery. Male carriers face lower immediate risk but still benefit from knowing their status. The intervention is not complex: awareness, compression stockings during pregnancy, possible anticoagulation in pregnancy, and avoiding certain medications.

HBB encodes the beta-globin protein, one of the two main components of hemoglobin. Hemoglobin carries oxygen from your lungs to every cell in your body. Beta-globin variants can distort the shape of red blood cells (sickle cell disease) or reduce the amount of hemoglobin produced (beta-thalassemia).

Pathogenic variants in HBB are more common in people with ancestry from Africa, the Mediterranean, the Middle East, and Southeast Asia. If both parents carry a mutation in HBB, their child has a 25% chance of inheriting two copies and developing either sickle cell disease or beta-thalassemia, both of which cause severe hemolytic anemia, pain crises, organ damage, and reduced lifespan without treatment. Sickle cell disease causes excruciating pain episodes, organ damage, and complications that demand lifelong medical management. Beta-thalassemia major causes severe anemia requiring regular blood transfusions from infancy.

If you’re a carrier and your partner is a carrier, early diagnosis of your child allows immediate access to newborn screening, penicillin prophylaxis to prevent infection, immunizations, and in some cases, curative bone marrow transplant. Knowing in advance transforms the outcome.

HLA-DQ2 is a gene that codes for a protein on the surface of immune cells. This protein presents gluten peptides to your immune system. If you carry HLA-DQ2, your immune system can recognize gluten as a threat and mount an attack against your own small intestine. Without HLA-DQ2, celiac disease cannot develop.

HLA-DQ2 is carried by roughly 30-40% of people of European ancestry, but only 2-3% of HLA-DQ2 carriers develop celiac disease. However, if your child inherits HLA-DQ2 and you or your partner has celiac disease, their risk of developing celiac rises significantly. Celiac disease causes intestinal inflammation, nutrient malabsorption, anemia, growth delays, neurological symptoms, and increased risk of autoimmune diseases and certain cancers if left untreated.

The good news: if your child has HLA-DQ2 and eventually develops celiac disease, the treatment is simple and curative: a gluten-free diet. The bad news: children are often misdiagnosed for years, suffering through constipation, diarrhea, abdominal pain, and growth problems before anyone suspects celiac. Knowing in advance that your child carries HLA-DQ2 and understanding your family risk allows you to watch for early symptoms, get earlier testing, and start the gluten-free diet sooner.